XTL Biopharmaceuticals reports setback with pain treatment

November

XTL Biopharmaceuticals Ltd., a biotech company based in Valley Cottage, announced a setback involving Bicifadine, its treatment for nerve pain associated with diabetes.

The company said that the study comparing the effectiveness of two doses of Bicifadine against a placebo failed to meet its primary objective. “We are all very disappointed with the results of the study,” Chief Executive Officer Ron Bentsur said in a written statement. “We will devote the next few days to further analyze the data and decide on the appropriate course of action for the Bicifadine program and for the company.”

This entry was posted on Tuesday, November 18th, 2008 at 2:16 pm by Jay Loomis.
You can follow any responses to this entry through the RSS 2.0 feed.
Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.